Transgene SA
TRGNF
$0.70
-$0.89-55.98%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -97.07% | -97.02% | -- | -- | 50.66% |
| Total Other Revenue | 50.12% | 53.14% | -30.31% | -28.65% | -39.99% |
| Total Revenue | -5.44% | -3.53% | -30.31% | -28.65% | -22.36% |
| Cost of Revenue | 33.17% | 35.85% | -2.04% | 0.28% | -2.78% |
| Gross Profit | -44.30% | -47.20% | -10.41% | -13.03% | -4.84% |
| SG&A Expenses | -15.11% | -13.40% | 38.64% | 41.92% | -0.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 59.15% | 62.35% | -109.99% | -110.23% | -59.36% |
| Total Operating Expenses | 23.13% | 25.61% | -2.32% | 0.00% | -2.84% |
| Operating Income | -29.24% | -31.84% | -6.38% | -8.90% | -2.68% |
| Income Before Tax | -169.44% | -174.85% | -2.51% | -4.94% | 61.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -169.44% | -174.85% | -2.51% | -4.94% | 61.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -169.44% | -174.85% | -2.51% | -4.94% | 61.37% |
| EBIT | -29.24% | -31.84% | -6.38% | -8.90% | -2.68% |
| EBITDA | -29.84% | -32.46% | -9.80% | -12.40% | -3.06% |
| EPS Basic | -106.45% | -110.43% | -1.38% | -3.75% | 61.81% |
| Normalized Basic EPS | -107.55% | -112.15% | -1.29% | -3.75% | 79.11% |
| EPS Diluted | -108.80% | -112.75% | -0.92% | -3.26% | 62.89% |
| Normalized Diluted EPS | -107.55% | -112.15% | -1.29% | -3.75% | 79.11% |
| Average Basic Shares Outstanding | 30.57% | 30.57% | 1.16% | 1.16% | 1.18% |
| Average Diluted Shares Outstanding | 30.57% | 30.57% | 1.16% | 1.16% | 1.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |